Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.

"Conflict of Interest Statement Hui-Chuan Sun has received honorarium or lecture fees from Roche, Bayer, MSD, Eisai, Hengrui, Innovent, TopAlliance, Abbott, Beigene, Gilead, and Zelgen during the last 5 years. Jia Fan is an Editorial Board Member of Liver Cancer. All remaining authors have no conflicts of interest to declare."

"This work was supported by the Leading Investigator Program of the Shanghai municipal government (17XD1401100), the National Key Basic Research Program (973 Program, 2015CB554005) from the Ministry of Science and Technology of China, the National Natural Science Foundation of China (81871928), the Special Research Fund for Liver Cancer Diagnosis and Treatment from the China Anti-Cancer Association (H2020-008), and the Clinical Research Special Fund of Zhongshan Hospital, Fudan University (2020ZSLC71) to Hui-Chuan Sun."